Laurence Jn Cooper

Title: Laurence Jn Cooper: Innovator in Canine Immunotherapy

Introduction

Laurence Jn Cooper is a prominent inventor based in Houston, TX (US). He has made significant contributions to the field of immunotherapy, particularly in the treatment of canine diseases. With a total of 3 patents, his work focuses on innovative approaches to enhance immunity in canines.

Latest Patents

One of his latest patents is titled "Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor." This invention relates to compositions and methods for treating canine CD20 positive diseases using modified canine T cells and pharmaceutical compositions for adoptive cell therapy. Another notable patent is "Chimeric antigen receptor molecules and uses thereof," which provides CAR polypeptides that bind to target antigens, specifically targeting CD123. These advancements represent a significant leap in veterinary medicine and immunotherapy.

Career Highlights

Laurence has worked with esteemed institutions such as the University of Texas System and the University of Pennsylvania. His experience in these organizations has allowed him to develop groundbreaking therapies that address critical health issues in canines.

Collaborations

He has collaborated with notable colleagues, including Simon Olivares and Hiroki Torikai, contributing to the advancement of research in his field.

Conclusion

Laurence Jn Cooper's innovative work in canine immunotherapy showcases his dedication to improving animal health through scientific advancements. His patents and collaborations highlight the importance of research in developing effective treatments for canine diseases.